Analysis for regression of atherosclerosis in acute coronary syndrome patients after PCSK9 inhibitor therapy by using near-infrared spectroscopy and intravascular ultrasound

Analysis for regression of atherosclerosis in acute coronary syndrome patients after PCSK9 inhibitor therapy by using near-infrared spectroscopy and intravascular ultrasound - Analysis for regression of atherosclerosis in acute coronary syndrome patients after PCSK9 inhibitor therapy by using near-infrared spectroscopy and intravascular ultrasound

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027238

Enrollment

Registered

2017-05-03

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary disease

Interventions

Using PCSK9 inhibitor therapy for acute coronary syndrome patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute coronary syndrome patients with the lesion which is different form culprit lesion

Exclusion criteria

Exclusion criteria: Patients with intolerance to PCSK9 inhibitor, intolerance to anti-coagulant and anti-platelet therapy, not crossing the NIRS-IVUS, severe complication (severe liver dysfunction, severe renal failure, uncontrolled hypertension), and unstable hemodynamics

Design outcomes

Primary

Measure	Time frame
The stenosis degree and the levels of lipid core burden index in the lesion which is different form culprit lesion after six months PCSK9 inhibitor therapy	—

Countries

Japan

Contacts

Public ContactNoriyuki Wakana

Kyoto Prefectural University of Medicine Cardiology

nw0920@koto.kpu-m.ac.jp075-251-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026